Answers are grounded in this paper and cite their sources.
Clinical trial reports long-term efficacy and safety outcomes of ocrelizumab in relapsing and primary progressive multiple sclerosis, highlighting decade-long therapeutic effects.
To assess the long-term efficacy and safety of ocrelizumab (OCR) in patients with relapsing and primary progressive multiple sclerosis (pwRMS/pwPPMS).
No takes yet. Share an insight, caveat, or question.
Hauser et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: